GTBP

GT Biopharma, Inc. (GTBP) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. GT Biopharma is a clinical-stage biopharmaceutical company developing immune-oncology products based on its proprietary TriKE® and Dual Targeting TriKE® platforms. The company operates as a single segment and is currently a non-accelerated filer and smaller reporting company. As of May 8, 2026, there were 36,062,904 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 47% to $2.85 million. Selling, general, and administrative (SG&A) expenses surged 188% to $2.44 million, driven by increased marketing and legal fees. Conversely, Research and Development (R&D) expenses decreased 62% to $413,000 due to reduced production costs.
• Other Income: Total other income dropped significantly from $1.16 million in Q1 2025 to $15,000 in Q1 2026. This decline was primarily due to the absence of a $998,000 gain on the settlement of a vendor payable recorded in the prior year.
• Financing Activity: The company raised approximately $4.6 million in Q1 2026 through the exercise of warrants and the issuance of Series L convertible preferred stock, compared to $616,000 in the prior year period.
• Equity Structure: Significant dilution occurred due to anti-dilution adjustments on warrants and the conversion of Series L preferred stock. The number of warrants outstanding increased to 57.55 million, with a weighted average exercise price of $0.62.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states that the company's financial condition raises substantial doubt about its ability to continue as a going concern within one year. The company has no approved products, no revenue, and expects losses to continue. It relies on additional financing to fund operations.
• NASDAQ Compliance: The company received notice of non-compliance with the $1.00 minimum bid price requirement. It has requested a second 180-day compliance period (until November 2026) to regain compliance, potentially via a reverse stock split. Failure to comply could result in delisting.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to a material weakness in accounting for complex financial transactions (specifically ASC 480 regarding Greenshoe Rights). Remediation efforts are ongoing.
• Legal Proceedings:
  • Ohri Matter: Arbitration against former CFO Manu Ohri regarding breach of fiduciary duties; mediation held March 31, 2026, with a hearing scheduled for October 2026.
  • Z-One Matter: A lawsuit regarding convertible notes was dismissed with prejudice in February 2026, but the plaintiff filed a notice of appeal in March 2026.
  • Silberfein/DiPietro/Werthman Matters: Three lawsuits regarding convertible notes are pending; the company has reached a settlement in principle and is finalizing terms.
• Clinical Pipeline:
  • GTB-3650: Phase 1 trial for AML/MDS is ongoing with approximately 50% of patients dosed.
  • GTB-5550: Phase 1a/1b trial for solid tumors received FDA clearance in January 2026; first patient dosed in May 2026.

Investor Verification Checklist

• Liquidity Runway: Verify if the $8.9 million cash balance is sufficient to fund operations through the next 12 months given the $2.5 million quarterly burn rate.
• Financing Terms: Review the specific terms of the Series L Preferred Stock and the "Committed Equity Facility" to understand potential future dilution and conversion triggers.
• NASDAQ Status: Monitor the outcome of the request for the second compliance period and the likelihood of a reverse stock split.
• Legal Settlements: Confirm the final terms of the settlements with Silberfein, DiPietro, and Werthman to assess potential cash outflows.
• Internal Control Remediation: Track the timeline for remediation of the material weakness in internal controls over financial reporting.